Heartburn, Gastroesophageal Reflux Disease
ConditionGERD
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age19+
SponsorIncheon St.Mary's Hospital
About this trial
Gastroesophageal reflux disease (GERD) is a condition caused by the reflux of stomach contents into the esophagus, presenting with typical symptoms such as heartburn and acid regurgitation.
GERD is a chronic condition that affects quality of life, and patients with this condition are known to have a lower quality of life compared to healthy individuals. In particular, nocturnal heartburn can lead to sleep deprivation and affect daily life, as well as overall quality of life.
This study aims to evaluate the efficacy of alleviating nocturnal heartburn symptoms in patients with erosive reflux disease (ERD).
Eligibility criteria
Qualifiers
Korean adults aged 19 years or older as of the date of written consent
Those diagnosed with erosive gastroesophageal reflux disease based on upper gastrointestinal endoscopy (EGD)
Those who reported nighttime heartburn for more than 3 months at the time of screening (Visit 1)
Those who voluntarily decided to participate and provide written informed consent
Disqualifiers
Those who cannot undergo upper gastrointestinal endoscopy (EGD)
Individuals with a history of drug or alcohol abuse (within the past year)
Individuals who have received other investigational products within one month prior to the screening visit (Visit 1)
In addition to the above, individuals with clinically significant findings that the investigator deems medically inappropriate for the present study
Trial design
Treatments tested in this trial
- Zastaprazan
- Esomeprazole
Treatment groups
160 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov